House Of Lords Validates Angiotech's Stent Patent

Law360, New York (July 10, 2008, 12:00 AM EDT) -- The United Kingdom's House of Lords ruled Wednesday that Angiotech Pharmaceuticals Inc.'s patent for a drug-eluting stent is not invalid for obviousness, overturning decisions by two lower courts and ending a nine-year legal battle.

The U.K.'s highest court ruled against Angiotech's American competitor Conor Medsystems Inc., which was one of five companies to challenge Angiotech's patent for taxol stent coating in various lawsuits in Europe.

Angiotech's stent is designed to prevent restenosis, or scarring of the artery, by eluting the drug taxol.

The House of Lords...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.